APIs para pesquisa e impurezas

3-(Methylamino)-5,6-dihydro-2H-1,4-thiazin-2-one oxime hydrochloride is an analytical reagent used for HPLC analysis of the impurities in pharmaceutical products. It is a white crystalline solid with a melting point of 235°C. 3-(Methylamino)-5,6-dihydro-2H-1,4-thiazin-2-one oxime hydrochloride is used as a reference standard and has been assigned CAS No. 112233-23-5 by the Chemical Abstracts Service (CAS). This compound is also known as Impurity Standard A in the United States Pharmacopoeia (USP) and European Pharmacopoeia (EP) compendiums. 3-(Methylamino)-5,6-dihydro-2H-1,4-thiazin-2-one oxime

Applications L-2-Aminobutyric Acid-d6 is the isotope labelled analog of L-2-Aminobutyric Acid (A602930); a receptor antagonist. References Porter, D.J.T., et al.: Biochem. Pharmacol., 50, 1475 (1995)

Olsalazine sodium impurity B is a synthetic compound that is used in the production of Olsalazine sodium. It is one of the metabolites of olsalazine and has been found to be more potent than olsalazine sodium. Olsalazine sodium impurity B is purified by HPLC and characterized by analytical methods such as UV, IR, melting point, NMR, and mass spectrometry. Impurity standard for this compound has not been established yet.

Please enquire for more information about 5-Ethenyl-2-oxo-3-pyrrolidinecarboxylic acid including the price, delivery time and more detailed product information at the technical inquiry form on this page

Applications p-Hexylresorcinol shows antiimnflammatory activity acting on the human 5-LO (5-Lipoxygenase) proinflammatory enzyme Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Filosa, R. et al.: Eur. j. Med. Chem., 67, 269 (2013);

Applications Suvorexant-d6 is the labeled analog of Suvorexant (S870000), a dual (non-selective) orexin receptor antagonist in development by Merck & Co. for the treatment of insomnia. It works by turning off wakefulness rather than by inducing sleep. Users of higher doses had an increased rate of suicidal ideation. References Cox, C., et al.: J. Med. Chem., 53, 5320 (2010); Baxter, C., et al.: Org. Process Res. Dev., 15, 367 (2011); Winrow, C., et al.: J. Neurogenet., 25, 52 (2011); Mieda, M., et al.: CNS Drugs, 27, 83 (2013); Osborne, R.: Nat. Rev. Drug Discov., 12, 492 (2013)